DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Susan Galbraith - 5 Pascal Soriot - 2 Soriot - 2 AstraZeneca - 1 AstraZeneca’s - 1 Ivan Menezes - 1 Debra Crew - 1 David Fredrickson - 1
Top related locs:
Swedish U.S radioconjugates AstraZeneca’s London
Top related orgs:
AstraZeneca - 5 Thomson - 3 Fusion - 2 U.S . Food - 2 Drug Administration - 2 FDA - 2 Fusion Pharmaceuticals - 1 Fusion Pharmaceuticals Inc - 1

Search resuls for: "Susan Galbraith"


6 mentions found


☆ AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
  + stars: | 2024-03-19 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomesDr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Persons: Susan Galbraith Organizations: AstraZeneca, Fusion, Fusion Pharmaceuticals
☆ AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
  + stars: | 2024-03-19 | by ( ) www.cnbc.com   time to read: +2 min
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates
☆ AstraZeneca succession sickness demands urgent fix
  + stars: | 2023-09-15 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +3 min
LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN.L) shares following an article stating boss Pascal Soriot may soon resign. The company has played down the report, and its stock has recovered, but the episode highlights its uncertain position were 64-year-old Soriot to leave. Without a clear succession plan, investors should prepare for further swings. Small wonder investors and analysts wonder whether AstraZeneca will be able to find a successor capable of replicating his success.
Persons: Pascal Soriot, AstraZeneca’s, Ivan Menezes, Debra Crew, Soriot, Susan Galbraith, David Fredrickson, Luke Miels, Soriot’s, Neil Unmack, Streisand Neto Organizations: Reuters, Pfizer, pharma, Novartis, Sanofi, GSK, AstraZeneca, Diageo, Thomson Locations: AstraZeneca’s, Swedish
☆ AstraZeneca CEO says lung cancer drug trial data 'very encouraging'
  + stars: | 2023-07-28 | by ( Maggie Fick Josephine Mason | Maggie Fick | Josephine Mason | ) www.reuters.com   time to read: +2 min
SummaryCompanies Plans to file trial data with FDAComments sooth some investor concernsAbsence of "clinically meaningful" in interim trial data worried investorsLONDON, July 28 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's (AZN.L) shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further. The company said on Friday it will continue with its plan to file data from the trial with the U.S. Food and Drug Administration (FDA), soothing some investor concerns. In a briefing with analysts, Susan Galbraith, executive vice president of oncology R&D, said the FDA response to the data so far had been "encouraging".
Persons: Pascal Soriot, Soriot, Susan Galbraith, Maggie Fick, Josephine Mason, David Evans, Susan Fenton Organizations: LONDON, AstraZeneca, U.S . Food, Drug Administration, FDA, U.S, Thomson
☆ AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
  + stars: | 2023-06-04 | by ( Natalie Grover | ) www.reuters.com   time to read: +2 min
LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene. In the trial, Tagrisso or a placebo was given to patients to assess whether the AstraZeneca therapy could keep their cancer at bay. An estimated 88% of patients treated with Tagrisso were alive at five years compared to 78% on placebo, trial data also showed. AstraZeneca is also expecting to provide details on the impact of combining Tagrisso with chemotherapy in patients with advanced EGFR-mutated lung cancer later this year.
Persons: Tagrisso, Susan Galbraith, Dave Fredrickson, Natalie Grover, Angus MacSwan Organizations: American Society of Clinical Oncology, AstraZeneca, Reuters, Thomson Locations: Swedish, London
☆ AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
  + stars: | 2022-11-29 | by ( ) www.reuters.com   time to read: +2 min
Nov 29 (Reuters) - AstraZeneca (AZN.L) will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis (NOVN.S) and Gilead (GILD.O). Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells. Linnemann founded Neogene in the Netherlands in 2018 along with the Netherlands Cancer Institute's Ton Schumacher. AstraZeneca will make an initial payment of $200 million to Neogene, with a further $120 million dependent on the company meeting certain targets.
0 next >>
Total: 6